Holen Sie sich die Stockscreener-App
5.31
3.01%
-0.18
Schlusskurs vom Vortag:
$5.49
Offen:
$5.57
24-Stunden-Volumen:
40,561
Relative Volume:
0.30
Marktkapitalisierung:
$55.88M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-73.52M
KGV:
-8.0455
EPS:
-0.66
Netto-Cashflow:
$-100.45M
1W Leistung:
+5.65%
1M Leistung:
+3.80%
6M Leistung:
-10.50%
1J Leistung:
-56.35%
1-Tages-Spanne:
$5.23
$5.57
1-Wochen-Bereich:
$4.94
$5.80
52-Wochen-Spanne:
$3.61
$12.54
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Vergleichen Sie DTIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.32 | 55.88M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.02 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.46 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.02 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
584.24 | 35.70B | 2.58B | 1.06B | -1.28B | 16.33 |
|
BNTX
Biontech Se Adr
|
108.56 | 27.19B | 2.97B | -812.83M | -1.24B | -3.3962 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
precision biosciences reports voting outcomes at annual shareholder meeting - Investing.com
Precision BioSciences Holds Annual Stockholder Meeting - TipRanks
Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus
(DTIL) Proactive Strategies - news.stocktradersdaily.com
Precision BioSciences: Q1 Earnings Snapshot - CT Insider
Precision BioSciences Reports Q1 2025 Financial Results - TipRanks
Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Precision BioSciences Reports Q1 Results and Business Update - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences Reports First Quarter 2025 Financial Resul - GuruFocus
DTIL Reports Strong Start to 2025 with Clinical Progress | DTIL Stock News - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | DTIL Stock News - GuruFocus
Precision Biosciences Q1 Income From Operations USD -22.112 Million - marketscreener.com
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Accelerates PBGENE-DMD Program for DMD - TipRanks
Precision BioSciences Accelerates Development of PBGENE-DMD With - GuruFocus
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - BioSpace
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 | DTIL Stock News - GuruFocus
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - GuruFocus
iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings - Business Wire
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting | DTIL Stock News - GuruFocus
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 29, 2025 - BioSpace
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Precision BioSciences Strengthens Gene Editing Team with Strategic RSU Awards to New Hires - Stock Titan
Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace
Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia
Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus
Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brown Melinda | Director |
Mar 26 '25 |
Buy |
4.75 |
1,839 |
8,735 |
9,057 |
| Germano Geno J | Director |
Mar 25 '25 |
Buy |
5.30 |
3,250 |
17,225 |
11,057 |
| Amoroso Michael | President and CEO |
Mar 24 '25 |
Sale |
5.56 |
964 |
5,360 |
109,540 |
1.47%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):